Late-stage trials evaluating the PD-1 inhibitor pembrolizumab in men with prostate cancer have all ended in failure, leading clinicians to conclude that new treatment strategies are needed to help make checkpoint blockade more effective in the immune-suppressed environment of most prostate tumors.

You do not currently have access to this content.